Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy

Pancreas

Volumn 37, Issue 3, 2008, Pages 269-274

  Wong, Derrick ^a   Ko, Andrew H ^a   Hwang, Jimmy ^a   Venook, Alan P ^a   Bergsland, Emily K ^a   Tempero, Margaret A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CA19 9; Chemotherapy; Pancreatic cancer; Surrogate; Tumor marker

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; DOWN REGULATION; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; PANCREAS TUMOR; RETROSPECTIVE STUDY; TIME;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 58049134458     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31816d8185     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53-55.
3. Mourant A, Kopec AC, Damaniewska-Sobczak K. The Distribution of the Human Blood Groups and Other Polymorphisms. London: Oxford University Press; 1976.
4. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501-5503.
5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350-355.
6. Yeo C, Tempero M, Abrams R. Pancreas Cancer: Clinical Management. Philadelphia, PA: Lippincott, Williams & Wilkins; 2002.
7. Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93: 195-199.
8. Ko AH, Dito E, Schillinger B, et al. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006;24:379-385.
9. Ko AH, Dito E, Schillinger B, et al. A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): update with completion of study accrual. J Clin Oncol. 2007;25:18S [Abstract 4548].
10. Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993;25:58-68.
11. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
12. Lundin J, Roberts PJ, Kuusela P, et al. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-519.
13. Sperti C, Pasquali C, Catalini S, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52: 137-141.
14. Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393-396.
15. Ikeda M, Okada S, Tokuuye K, et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001;91:490-495.
16. Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:90-97.
17. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32: 35-41.
18. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743.
19. Okusaka T, Okada S, Sato T, et al. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998;45:867-872.
20. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003;26:462-467.
21. Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016.
22. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-1417.
23. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182-1191.
24. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22: 3776-3783.
25. Stern P, Friedecky B, et al. Comparison of different immunoassays for CA 19-9. Clin Chem Lab Med. 2001;39:1278-1282.